Bank of America’s Intra-Cellular Therapies Inc. ITCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-1,815,287
| Closed | -$239M | – | 8792 |
|
|
2025
Q1 | $239M | Buy |
1,815,287
+1,450,917
| +398% | +$181M | 0.02% | 643 |
|
|
2024
Q4 | $30.4M | Sell |
364,370
-58,139
| -14% | -$4.78M | ﹤0.01% | 1907 |
|
|
2024
Q3 | $30.9M | Sell |
422,509
-125,207
| -23% | -$9.41M | ﹤0.01% | 1987 |
|
|
2024
Q2 | $37.5M | Sell |
547,716
-14,609
| -3% | -$1.01M | ﹤0.01% | 1676 |
|
|
2024
Q1 | $38.9M | Buy |
562,325
+79,031
| +16% | +$5.43M | ﹤0.01% | 1681 |
|
|
2023
Q4 | $34.6M | Buy |
483,294
+85,626
| +22% | +$4.93M | ﹤0.01% | 1640 |
|
|
2023
Q3 | $20.7M | Sell |
397,668
-157,451
| -28% | -$9.17M | ﹤0.01% | 1998 |
|
|
2023
Q2 | $35.2M | Buy |
555,119
+273,991
| +97% | +$17.1M | ﹤0.01% | 1575 |
|
|
2023
Q1 | $15.2M | Buy |
281,128
+104,718
| +59% | +$5.06M | ﹤0.01% | 2399 |
|
|
2022
Q4 | $9.34M | Buy |
176,410
+4,225
| +2% | +$212K | ﹤0.01% | 2753 |
|
|
2022
Q3 | $8.01M | Sell |
172,185
-13,555
| -7% | -$708K | ﹤0.01% | 2845 |
|
|
2022
Q2 | $10.6M | Sell |
185,740
-2,820
| -1% | -$160K | ﹤0.01% | 2635 |
|
|
2022
Q1 | $11.5M | Buy |
188,560
+68,112
| +57% | +$3.54M | ﹤0.01% | 2725 |
|
|
2021
Q4 | $6.3M | Buy |
120,448
+37,644
| +45% | +$1.58M | ﹤0.01% | 3416 |
|
|
2021
Q3 | $3.09M | Sell |
82,804
-4,226
| -5% | -$147K | ﹤0.01% | 4040 |
|
|
2021
Q2 | $3.55M | Sell |
87,030
-135,278
| -61% | -$5M | ﹤0.01% | 3835 |
|
|
2021
Q1 | $7.54M | Buy |
222,308
+64,393
| +41% | +$2.23M | ﹤0.01% | 2998 |
|
|
2020
Q4 | $5.02M | Buy |
157,915
+85,322
| +118% | +$2.24M | ﹤0.01% | 3122 |
|
|
2020
Q3 | $1.86M | Buy |
72,593
+5,163
| +8% | +$118K | ﹤0.01% | 3737 |
|
|
2020
Q2 | $1.73M | Sell |
67,430
-26,792
| -28% | -$542K | ﹤0.01% | 3737 |
|
|
2020
Q1 | $1.45M | Buy |
94,222
+5,473
| +6% | +$119K | ﹤0.01% | 3739 |
|
|
2019
Q4 | $3.04M | Sell |
88,749
-17,587
| -17% | -$211K | ﹤0.01% | 3681 |
|
|
2019
Q3 | $795K | Buy |
106,336
+57,149
| +116% | +$548K | ﹤0.01% | 4720 |
|
|
2019
Q2 | $639K | Sell |
49,187
-70,981
| -59% | -$910K | ﹤0.01% | 4896 |
|
|
2019
Q1 | $1.46M | Sell |
120,168
-159,435
| -57% | -$2.04M | ﹤0.01% | 4238 |
|
|
2018
Q4 | $3.19M | Sell |
279,603
-372,318
| -57% | -$6.01M | ﹤0.01% | 3447 |
|
|
2018
Q3 | $14.1M | Buy |
651,921
+84,953
| +15% | +$1.78M | ﹤0.01% | 2133 |
|
|
2018
Q2 | $10M | Sell |
566,968
-99,748
| -15% | -$2.03M | ﹤0.01% | 2461 |
|
|
2018
Q1 | $14M | Buy |
666,716
+4,916
| +0.7% | +$95.8K | ﹤0.01% | 2097 |
|
|
2017
Q4 | $9.58M | Sell |
661,800
-144,034
| -18% | -$2.22M | ﹤0.01% | 2488 |
|
|
2017
Q3 | $12.7M | Sell |
805,834
-125,663
| -13% | -$1.84M | ﹤0.01% | 2273 |
|
|
2017
Q2 | $11.6M | Buy |
931,497
+921,837
| +9,543% | +$10.7M | ﹤0.01% | 2222 |
|
|
2017
Q1 | $157K | Buy |
9,660
+3,363
| +53% | +$48.7K | ﹤0.01% | 5422 |
|
|
2016
Q4 | $95K | Sell |
6,297
-18,145
| -74% | -$256K | ﹤0.01% | 5652 |
|
|
2016
Q3 | $373K | Buy |
24,442
+22,372
| +1,081% | +$905K | ﹤0.01% | 4817 |
|
|
2016
Q2 | $80K | Buy |
2,070
+1,257
| +155% | +$45.2K | ﹤0.01% | 5637 |
|
|
2016
Q1 | $23K | Sell |
813
-351
| -30% | -$11.7K | ﹤0.01% | 6088 |
|
|
2015
Q4 | $63K | Buy |
1,164
+783
| +206% | +$39.5K | ﹤0.01% | 5942 |
|
|
2015
Q3 | $15K | Sell |
381
-11,245
| -97% | -$367K | ﹤0.01% | 6426 |
|
|
2015
Q2 | $371K | Buy |
+11,626
| New | +$295K | ﹤0.01% | 4910 |
|
|
2014
Q4 | – | Sell |
-177
| Closed | -$2K | – | 8021 |
|
|
2014
Q3 | $2K | Sell |
177
-4,219
| -96% | -$63.4K | ﹤0.01% | 7802 |
|
|
2014
Q2 | $74K | Buy |
+4,396
| New | +$72.7K | ﹤0.01% | 6362 |
|
Other funds holding ITCI
KIM
HNB
Bank of America's ITCI Position: Q2 2025 in Review
Bank of America sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 1,815,287 shares — an estimated $239M sold.
Bank of America first reported a position in ITCI in Q2 2014 and held it in 42 quarters. The position peaked at $239M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.
- Bank of America reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
- Bank of America sold 1,815,287 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $239M.
- Bank of America first reported a position in Intra-Cellular Therapies Inc. in Q2 2014 and held it in 42 quarters.
- Bank of America's Intra-Cellular Therapies Inc. position peaked at $239M in Q1 2025.
- 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.
Based on Bank of America's 13F filing for Q2 2025, filed 14 Aug 2025.